Improvements in Quality of Life and Itch Symptoms with Dupilumab in Patients with Atopic Dermatitis: A Targeted Literature Review and Meta-Analysis of Real-World Studies
Main Article Content
Keywords
Atopic Dermatitis, Dermatology Life Quality Index, Dupilumab, Itch Symptoms, Meta-Analysis
References
1. Dupixent, INN – Dupilumab – European Medicines Agency. SmPC. 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent. Accessed August 5, 2023.
2. Halling, A.S., et al. J Am Acad Dermatol. 2021; 84(1): 139–147.
3. Fujiwara, C, et al. J Cutan Immun Allergy. 2023; 6(3): 88–93.
4. Hongbo, Y, et al. J Invest Dermatol. 2005;125: 659–64.
5. Reich, A, et al. Acta Derm Venereol. 2017; 97(6): 759–760.
2. Halling, A.S., et al. J Am Acad Dermatol. 2021; 84(1): 139–147.
3. Fujiwara, C, et al. J Cutan Immun Allergy. 2023; 6(3): 88–93.
4. Hongbo, Y, et al. J Invest Dermatol. 2005;125: 659–64.
5. Reich, A, et al. Acta Derm Venereol. 2017; 97(6): 759–760.